Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | STAT1 | P42224 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21550152 | 0.88 | POLB (0.43) | POLBALDH1A1S1PR1 | |
| SCHEMBL21550082 | 0.87 | POLB (0.42) | POLBMEN1NPC1ALDH1A1STAT3 | |
| SCHEMBL19712043 | 0.85 | POLB (0.42) | POLB | |
| SCHEMBL21609575 | 0.84 | POLB (0.45) | POLBMEN1KMT2AS1PR1 | |
| SCHEMBL19712002 | 0.84 | POLB (0.43) | POLBMEN1KMT2A | |
| SCHEMBL21609571 | 0.84 | POLB (0.46) | POLBMEN1NPC1ALDH1A1STAT3 | |
| SCHEMBL21805955 | 0.84 | POLB (0.41) | POLBALDH1A1 | |
| SCHEMBL21550144 | 0.84 | POLB (0.41) | POLBMEN1NPC1ALDH1A1STAT3 | |
| SCHEMBL21550142 | 0.84 | POLB (0.41) | POLB | |
| SCHEMBL29358501 | 0.84 | POLB (0.41) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257853-B1 | CONDENSED HETEROCYCLIC COMPOUND AND NOXIOUS ORGANISM CONTROL AGENT | NISSAN CHEMICAL CORP (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-20210017194-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AND PESTICIDES | NISSAN CHEMICAL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| US-10882869-B2 | Condensed heterocyclic compounds and pesticides | NISSAN CHEMICAL CORPORATION (JP) | 2021-01-05 | — | — | US | disclosed |
| US-10464950-B2 | Condensed heterocyclic compounds and pesticides | NISSAN CHEMICAL CORPORATION (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20180022760-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AND PESTICIDES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-01-25 | — | — | US | disclosed |
| EP-3257853-A1 | CONDENSED HETEROCYCLIC COMPOUND AND NOXIOUS ORGANISM CONTROL AGENT | Nissan Chemical Industries, Ltd. (JP) | 2017-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022760-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AND PESTICIDES | HDAC3, CHRM3, NR1D2 | POLB 4146/4885MEN1 3122/4885NPC1 382/4885 |
| US-10882869-B2 | Condensed heterocyclic compounds and pesticides | CNPY3, CNPY2, CHRM1 | POLB 3806/4885MEN1 615/4885NPC1 2793/4885 |
| US-20210017194-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AND PESTICIDES | HDAC3, CHRM3, NR1D2 | POLB 4146/4885MEN1 3122/4885NPC1 382/4885 |
| US-10464950-B2 | Condensed heterocyclic compounds and pesticides | HDAC3, CHRM3, NR1D2 | POLB 4146/4885MEN1 3122/4885NPC1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.